The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Rho GTPases modulate malignant transformation of tumor cells
Open accessAbstract
Rho GTPases are involved in the acquisition of all the hallmarks of cancer, which comprise 6 biological capabilities acquired during the development of human tumors. The hallmarks include proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis programs, as defined by Hanahan and Weinberg. (1) Controlling these hallmarks are genome instability and inflammation. Emerging hallmarks are reprogramming of energy metabolism and evading immune destruction. To give a different view to the readers, we will not be focusing on invasion, metastasis, or cytoskeletal remodeling, but we will review here how Rho GTPases contribute to other hallmarks of cancer with a special emphasis on malignant transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“Inappropriate EGFR signaling contributes to tumor progression through activation of mitogenic signaling pathways.(104) Therefore, EGFR activity must be tightly regulated by different mechanisms, such as ligand-mediated receptor activation and through endocytosis and recycling/degradation.”
BackgroundA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 7×
“A mutation in a homologous residue in Rac2 has also been found in melanoma, along with a mutation in Cdc42.(27) Rac1 is a recurrent somatic missense mutation at codon 29 that results in substitution of a proline to a serine residue.”
BackgroundInfluentialThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“However, in most malignancies, STAT proteins and particularly STAT3, are aberrantly activated (tyrosine phosphorylation).(189,190) Some of the tumor-intrinsic functions of activated STAT3 include: inhibition of differentiation, cancer stem cell expansion and/or survival (WNT5A, CD44, and jagged), proliferation (stimul…”
BackgroundCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“Ras-promoted oncogenic transformation Ras GTPase family of proteins are the most frequently mutated genes in cancer.(25,26) Several studies reported that Ras transformation of rodent fibroblasts is prevented by inhibitory mutants of RhoA,(79,82,85,86,89) RhoB,(80) RhoG,(86) Rac1,(79,84,86) TC10,(81)and Cdc42;(83) wher…”
BackgroundCellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · cited 1×
“Activated Rac1 has increased binding activity toward Rac1 effectors and mutated Rac1 induces increased cell proliferation, altered cell migration, and stimulates membrane ruffling and MAPK signaling.(28) Other transforming Rac mutations (Rac1, Rac1, Rac2, Rac2) have also been found in human cancer cell lines.”
Background
Cited by
Are cancer cells really softer than normal cells?
Alibert, C., Goud, B., & Manneville, J. (2017) · Biology of the Cell · doi:10.1111/boc.201600078 · Cited by 366
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
Self-citationOrgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
Self-citationTargeting Rac and Cdc42 GEFs in Metastatic Cancer
Maldonado, M. D. M., Medina, J. I., Velazquez, L., & Dharmawardhane, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00201 · Cited by 122
“…recent reviews have discussed the relevance, especially of RhoA and RhoC signaling in cancer, and thus, all three GTPases Rho, Rac, and Cdc42 are potential targets for anticancer drug development (Orgaz et al., 2014; Aspenström, 2018; Svensmark and Brakebusch, 2019; Porazinski et al., 2020).”
BackgroundRhoA GTPase oxidation stimulates cell proliferation via nuclear factor-κB activation
Kim, J.-G., Kwon, H.-J., Wu, G., Park, Y., Lee, J.-Y., Kim, J., Kim, S.-C., Choe, M., Kang, S. G., Seo, G.-Y., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.013 · Cited by 31
Tyr42 phosphorylation of RhoA GTPase promotes tumorigenesis through nuclear factor (NF)-κB
Kim, J.-G., Choi, K.-C., Hong, C.-W., Park, H.-S., Choi, E.-K., Kim, Y.-S., & Park, J.-B. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.013 · Cited by 28
Metadata
- Authors
- Orgaz, J. L., Herraiz, C., & Sanz-Moreno, V.
- Venue
- Small GTPases
- Publisher
- Informa UK Limited
- Published
- 2014-10-02
- Volume
- 5
- Issue
- 4
- Pages
- e983867
- ISSN
- 2154-1248 (ISSN-L)
- 2154-1256
- OpenAlex
- W2051747485
- Cited by
- 177
- References
- 24
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.